ライフサイエンスコーパス: unclassifiable

1 ther patterns were subcortical myoclonus and unclassifiable.

2 2%), respectively, and 144 studies (5%) were unclassifiable.

3 Approximately 10% of the patients were unclassifiable.

4 as HF with reduced LVEF, and 29 (15.3%) were unclassifiable.

5 1% (n=4), G6a: 1% (n=8), G6e: <1% (n=1), and unclassifiable: 1% (n=9).

6 to 6.1%, p < 0.0001), and 41.7% decrease in unclassifiable (13.9% to 8.1%, p < 0.0001) scans during

7 9.8%)/122 (41.2%)/33 (11.2%)/112 (37.8%) and unclassifiable: 17 (5.7%).

8 lomonocytic leukemia (CMML; 48%) and MDS/MPD-unclassifiable (38%).

9 L, 122 germinal center B-cell-like-DLBCL, 18 unclassifiable, and 46 unknowns.

10 lomonocytic leukemia, isolated 5q- syndrome, unclassifiable, and therapy-related MDS were excluded.

11 Research on Cancer as probable, possible, or unclassifiable as to carcinogenicity are found to have g

12 (n = 15), primary effusion lymphoma (n = 7), unclassifiable B-cell NHL (n = 2), and Burkitt lymphoma

13 uring clinical subtyping, some patients were unclassifiable by the 2011 guidelines whereas others sim

14 The ten patients who were initially unclassifiable by the LPD analyses were subclassified by

15 ardial infarction and definite, possible, or unclassifiable coronary deaths in men and women aged 35-

16 ets of the virome and bacterial composition (unclassifiable "dark matter" and phages) and diet (eukar

17 related; 1076 non-AIDS-defining; 509 unknown/unclassifiable deaths).

18 chaemia, 92 critical limb ischaemia); and 62 unclassifiable deaths.

19 latter of which included both ABC DLBCL and unclassifiable DLBCL) on the basis of immunophenotype by

20 Interestingly, most of the unclassifiable-DLBCL by GEP showed a strong similarity t

21 frequently with absence seizures); Group 5, unclassifiable epilepsy (n = 127); and Group 6, neurodev

22 icipants with newly diagnosed generalised or unclassifiable epilepsy.

23 tory central cell and the remaining two were unclassifiable excitatory cells.

24 concluded that exposure to microplastics is "unclassifiable" for birth outcomes and gestational age i

25 avium and in one patient a microbiologically unclassifiable fungal infection.

26 sts that patients with progressive fibrosing unclassifiable ILD could benefit from pirfenidone treatm

27 ged >=18-85 years) had progressive fibrosing unclassifiable ILD, a percent predicted forced vital cap

28 tment for patients with progressive fibrotic unclassifiable ILD.

29 idone in patients with progressive fibrosing unclassifiable ILD.

30 ptom criteria were applied, 100 (21.6%) were unclassifiable including 21 (21.0%) with definite pulmon

31 th right temporal lobe presentations, and 11 unclassifiable including eight with motor neuron disease

32 approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is

33 pression (1 B-CLL, 1 blastoid mantle cell, 1 unclassifiable low grade B-cell lymphoma).

34 4%) had follicular lymphoma, and 6 (12%) had unclassifiable low-grade B-cell lymphoma.

35 al BCR-activating mutations or were LymphGen-unclassifiable (LymphGen-Other).

36 kin's lymphoma (3%), B-cell lymphoma (1.4%), unclassifiable lymphoma (2.8%), or a diagnosis other tha

37 tinctive enough to allow its separation from unclassifiable MDS/MPN (MDS/MPN-U).

38 yelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are a group of rare and heter

39 ocytosis (MDS/MPN-RS-T; n = 71), and MDS/MPN unclassifiable (MDS/MPN-U; n = 106).

40 19 lentigo maligna melanomas, 18 AMs, and 12 unclassifiable melanomas) using fluorescence in situ hyb

41 Combining the unclassifiable MI group with either STEMI or NSTEMI did

42 vents occurred (829 NSTEMIs, 249 STEMIs, 296 unclassifiable MIs).

43 urine MPN model with features of a pediatric unclassifiable mixed MDS/MPN and mimics many clinical ma

44 (ET); primary myelofibrosis (PMF); and MPN, unclassifiable (MPN,U).

45 vera, 547 with myelofibrosis, and 1720 with unclassifiable MPNs) and 4.3 (95% CI, 4.1-4.4) for the 7

46 myelofibrosis, and 1.5 (95% CI, 1.1-2.1) for unclassifiable MPNs.

47 themia, polycythemia vera, myelofibrosis, or unclassifiable MPNs.

48 mplex class I (43 IBM, 6 polymyositis, and 9 unclassifiable myositis), and 9 controls.

49 ant had either focal (n = 97, Groups 1-3) or unclassifiable (n = 39) epilepsy, whereas 34 individuals

50 either generalized (n = 14), no (n = 11) or unclassifiable (n = 6) epilepsy; only three had developm

51 ified 6217 PV, 2838 ET, 1172 MF, and 812 MPN unclassifiable (NOS) patients diagnosed in Sweden, 43 55

52 .9%) as "probable asthma," 1,193 (29.1%) as "unclassifiable obstructive airway disease, " 626 (15.3%)

53 .8%) as "probable asthma," 1,996 (31.1%) as "unclassifiable obstructive airway disease," 228 (3.5%) a

54 ciation with apraclonidine was unassessable, unclassifiable, or unlikely based on the World Health Or

55 pes of microalgae, protists, and an array of unclassifiable organisms.

56 Longitudinal evaluations of initially unclassifiable patients showed that the semantic variant

57 n-subtype B viruses in both classifiable and unclassifiable PR genes, with 36I being the predominant

58 s were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global c

59 0%), 6 (1.8%), 6n (4.8%), 6 v (0.2%) and one unclassifiable recombinant specimen (0.2%) also identifi

60 for FIB-4 in the derivation dataset yielded unclassifiable results in 686 (23%) individuals, and 139

61 s for APRI in the derivation dataset yielded unclassifiable results in 706 (24%) individuals, and 153

62 , atypical chronic myeloid leukemia, MDS/MPN-Unclassifiable, ring sideroblasts associated with marked

63 ) with two or more unprovoked generalised or unclassifiable seizures.

64 Compared with classifiable PR sequences, unclassifiable sequences had significantly more dual and

65 improvements include redesigned handling of unclassifiable species hypotheses, integration with the

66 For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibros

67 ischaemic stroke, intracranial haemorrhage, unclassifiable stroke, or systemic embolism at 90 days.

68 troke, symptomatic intracranial haemorrhage, unclassifiable stroke, or systemic embolism incidence at

69 nsonism associated with chromosome 17, three unclassifiable tauopathy, and one argyrophilic grain dis

70 26 (40%) of 65 cases with low-confidence or unclassifiable TBLC diagnoses, SLB reclassified six (23%

71 ach), 22 were subtype A1 (10.2%), and 9 were unclassifiable (UC) (4.2%).

72 PTCL-unclassifiable was molecularly heterogeneous, but we wer

73 s from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR